Urinary CYFRA 21.1 Is Not a Useful Marker for the Detection of Recurrences in the Follow-Up of Superficial Bladder Cancer

European Urology

Volumn 51, Issue 5, 2007, Pages 1267-1274

  Fernandez Gomez, Jesus ^a   Rodríguez Martínez, Juan J ^a   Barmadah, Safwan Escaf ^a   García Rodríguez, Jorge ^a   Allende, Dra Maite ^a   Jalon, Antonio ^a   Gonzalez, Roberto ^a   Álvarez Múgica, Miguel ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Bladder cancer; CYFRA 21.1; Follow up; Urine markers

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER SIZE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC VALUE; FOLLOW UP; HEMOGLOBIN DIPSTICK; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; NEGATIVE PREDICTIVE VALUE; POSITIVE PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; RECURRENT CANCER; ROC CURVE; SENSITIVITY AND SPECIFICITY; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; URINALYSIS; URINE CYTOLOGY;

ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; CYTODIAGNOSIS; HEMOGLOBINOMETRY; HUMANS; KERATINS; NEOPLASM RECURRENCE, LOCAL; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINE;

EID: 33947222995     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.12.019     Document Type: Article

References (25)

1. Droller M.J. Bladder cancer: state-of-the-art care. Cancer J Clin 48 (1998) 269-284
2. Tinzl M., and Marberger M. Urinary markers for detecting bladder cancer. EAU Update Series 1 (2003) 64-70
3. Glas A.S., Roos D., Deutekom M., et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 169 (2003) 1975-1982
4. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta 340 (2004) 57-65
5. Droller M.J. Current concepts of tumor markers in bladder cancer. Urol Clin North Am 29 (2002) 229-234
6. Passerotti C.C., Bonfim A., Martins J.R., et al. Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder. Eur Urol 49 (2006) 71-75
7. Shariat S.F., Matsumoto K., Casella R., et al. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol 48 (2005) 69-76
8. Konety B.R., and Getzenberg R.H. Urine based markers of urological malignancy. J Urol 165 (2001) 600-611
9. van Rhijn B.W., van der Poel H.G., and van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47 (2005) 736-748
10. Sanchez-Carbayo M., Urrutia M., Gonzalez de Buitrago J.M., et al. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 92 (2001) 2820-2828
11. Southgate J., Harnden P., and Trejdosiewicz L.K. Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histol Histopathol 14 (1999) 657-664
12. van der Gaast A., Schoenmakers C.H., Kok T.C., et al. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br J Cancer 69 (1994) 525-528
13. Niklinski J., Furman M., Chyczewska E., et al. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. Eur Respir J 8 (1995) 291-294
14. Andreadis C., Touloupidis S., Galaktidou G., et al. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. J Urol 174 (2005) 1771-1775
15. Pariente J.L., Bordenave L., Michel P., et al. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 158 (1997) 338-341
16. Senga Y., Kimura G., Hattori T., et al. Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer. Urology 48 (1996) 703-710
17. Morita T., Kikuchi T., Hashimoto S., et al. Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer. Eur Urol 32 (1997) 237-244
18. Dittadi R., Barioli P., Gion M., et al. Standardization of assay for cytokeratin-related tumor marker CYFRA21.1 in urine samples. Clin Chem 42 (1996) 1634-1638
19. Schambeck C.M., Stieber P., Schmeller N., et al. CYFRA 21-1 quantity measurement in the urine of patients with carcinoma of the urinary bladder and tract. Anticancer Res 17 (1997) 3063-3065
20. el-Ahmady O., Halim A.B., el-Din A.G., et al. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience. Anticancer Res 19 4A (1999) 2603-2608
21. Nisman B., Barak V., Shapiro A., et al. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 94 (2002) 2914-2922
22. Sanchez-Carbayo M., Espasa A., Chinchilla V., et al. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 45 (1999) 1944-1953
23. Shariat S.F., Herman M.P., Casella R., et al. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol 48 (2005) 424-431
24. ® test in the diagnosis of superficial bladder cancer. Eur Urol 48 (2005) 951-956
25. Sharma S., Zippe C.D., Pandrangi L., et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 162 (1999) 53-57